secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ernexa Therapeutics Inc. (ERNA)
CIK:        0000748592
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001140361-23-012545
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Eterna Therapeutics posts FY2022 net loss $24.6M; licenses iPSC tech to Lineage, subleases BMS space
--------------------------------------------------------------------------------

- Net loss for Q4 2022 was $4.5M ($1.24 per share); full year net loss $24.6M ($8.06 per share).
- Cash and restricted cash $15.5M as of Dec 31, 2022; $4.1M restricted for BMS sublease.
- Entered income-generating license agreement with Lineage Cell Therapeutics for gene-edited iPSC lines for neurology indications.
- Subleased 45,000 sq. ft. from BMS at Cambridge Crossing; BMS provides $8.6M for build-out.
- Appointed Matt Angel, Ph.D. as permanent CEO and President (previously interim).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/0001140361-23-012545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/748592/000114036123012545/brhc10050022_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-23-012545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer